Fibroblast growth factor 21 is a metabolic regulator that plays a role in the adaptation to ketosis
| Autor: | Eleni M Domouzoglou, Eleftheria Maratos-Flier |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
FGF21 medicine.medical_treatment Regulator Medicine (miscellaneous) Adipose tissue Peroxisome proliferator-activated receptor Biology Fibroblast growth factor Mice Internal medicine medicine Animals Humans PPAR alpha Obesity chemistry.chemical_classification Mice Knockout Nutrition and Dietetics Metabolic disorder Fatty Acids Fasting Ketosis medicine.disease Adaptation Physiological Fibroblast Growth Factors PPAR gamma Endocrinology Glucose chemistry Adipose Tissue Liver Diet Ketogenic Oxidation-Reduction Ketogenic diet |
| Zdroj: | The American journal of clinical nutrition. 93(4) |
| ISSN: | 1938-3207 |
| Popis: | Fibroblast growth factor 21 (FGF21) was originally identified as a member of the FGF family in homology studies and is a member of the endocrine FGF subfamily that lacks heparin binding domains and is released into the circulation. A potential role as a metabolic regulator emerged when FGF21 was shown to increase glucose uptake in adipocytes. Subsequently, marked elevations in FGF21 expression were observed in mice that ate a ketogenic diet and when fasting, which suggests that FGF21 expression plays a role in the adaptation to metabolic states that require increased fatty acid oxidation. Consistent with this evidence, FGF21 knockout mice were not able to respond appropriately to consumption of a ketogenic diet. FGF21 expression is downstream of peroxisome proliferator-activated receptor (PPAR) α in the liver and PPARγ in adipose tissue. FGF21 concentrations are higher in both rodent and human obesity, and recent data suggest that obesity may be an FGF21-resistant state. Recent data increasingly suggest that FGF21 is an important metabolic regulator that may have potential clinical implications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|